Zhejiang Nhu Co Ltd
SZSE:002001

Watchlist Manager
Zhejiang Nhu Co Ltd Logo
Zhejiang Nhu Co Ltd
SZSE:002001
Watchlist
Price: 21.58 CNY 0.42%
Market Cap: 66.3B CNY
Have any thoughts about
Zhejiang Nhu Co Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Zhejiang Nhu Co Ltd stock under the Base Case scenario is 33.56 CNY. Compared to the current market price of 21.58 CNY, Zhejiang Nhu Co Ltd is Undervalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
33.56 CNY
Undervaluation 36%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.3
P/S
P/S
Price to Sales
3.3
vs History
85
vs Industry
31
Median 3Y
3.6
Median 5Y
4.2
Industry
2.5
Forward
3.2
More Details
14.4
P/E
P/E
Price to Earnings
14.4
vs History
82
vs Industry
22
Median 3Y
17.4
Median 5Y
16.6
Industry
21.4
Forward
12.6
More Details
9.4
P/OCF
P/OCF
Price to OCF
9.4
vs History
98
vs Industry
32
Median 3Y
11.6
Median 5Y
13.5
Industry
16
More Details
19.1
P/FCFE
P/FCFE
Price to FCFE
19.1
vs History
77
vs Industry
2
Median 3Y
28.6
Median 5Y
26.2
Industry
23.3
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
42
vs Industry
31
Median 3Y
2.6
Median 5Y
2.5
Industry
2.1
More Details
3.5
EV/S
EV/S
Enterprise Value to Sales
3.5
vs History
88
vs Industry
28
Median 3Y
3.7
Median 5Y
4.5
Industry
2.6
Forward
3.4
More Details
9.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.5
vs History
82
vs Industry
14
Median 3Y
10.9
Median 5Y
10.5
Industry
5.1
More Details
12.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.5
vs History
84
vs Industry
19
Median 3Y
15
Median 5Y
14.3
Industry
13.7
Forward
8
More Details
12.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.5
vs History
84
vs Industry
22
Median 3Y
15
Median 5Y
14.3
Industry
16.7
Forward
10.5
More Details
9.9
EV/OCF
EV/OCF
Enterprise Value to OCF
9.9
vs History
98
vs Industry
30
Median 3Y
12.5
Median 5Y
13.9
Industry
15.1
More Details
14.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
14.3
vs History
58
vs Industry
8
Median 3Y
22.3
Median 5Y
20.5
Industry
18.9
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
44
vs Industry
35
Median 3Y
2.1
Median 5Y
2.1
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Zhejiang Nhu Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Nhu Co Ltd
SZSE:002001
66B CNY 3.3 14.4 12.5 12.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
726.7B USD 17.8 86.8 46.7 52.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.1 28.8 20 22.9
US
Johnson & Johnson
NYSE:JNJ
345.8B USD 3.9 23.6 11.4 14.8
US
Merck & Co Inc
NYSE:MRK
252.5B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
205.3B CHF 3.5 17.9 10 11.9
UK
AstraZeneca PLC
LSE:AZN
166.1B GBP 4.2 32.3 170.9 256.2
CH
Novartis AG
SIX:NOVN
174B CHF 3.9 10.9 9.5 13.2
US
Pfizer Inc
NYSE:PFE
152.4B USD 2.5 35.8 10.6 16.1
P/E Multiple
Earnings Growth PEG
CN
Zhejiang Nhu Co Ltd
SZSE:002001
Average P/E: 30.1
14.4
32%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
86.8
76%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
28.8
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.6
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
17.9
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
32.3
40%
0.8
CH
Novartis AG
SIX:NOVN
10.9
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.8
102%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Zhejiang Nhu Co Ltd
SZSE:002001
Average EV/EBITDA: 414.9
12.5
45%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.7
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.4
4%
2.9
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10
7%
1.4
UK
AstraZeneca PLC
LSE:AZN
170.9
18%
9.5
CH
Novartis AG
SIX:NOVN
9.5
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Zhejiang Nhu Co Ltd
SZSE:002001
Average EV/EBIT: 1 811.5
12.5
32%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.1
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
22.9
22%
1
US
Johnson & Johnson
NYSE:JNJ
14.8
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
11.9
9%
1.3
UK
AstraZeneca PLC
LSE:AZN
256.2
32%
8
CH
Novartis AG
SIX:NOVN
13.2
17%
0.8
US
Pfizer Inc
NYSE:PFE
16.1
19%
0.8

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 214,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.